BiotechTube

Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ + Comparator: placebo (concomitant-vaccine matched) + Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Herpes Zoster

Conditions

Herpes Zoster, Pneumococcal Infection

Trial Timeline

Jun 1, 2007 → Feb 1, 2008

NCT ID
NCT00535730

About Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ + Comparator: placebo (concomitant-vaccine matched) + Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23

Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ + Comparator: placebo (concomitant-vaccine matched) + Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23 is a phase 3 stage product being developed by Merck for Herpes Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT00535730. Target conditions include Herpes Zoster, Pneumococcal Infection.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00535730Phase 3Completed

Competing Products

20 competing products in Herpes Zoster

See all competitors
ProductCompanyStageHype Score
ASP2151 + Valacyclovir hydrochlorideAstellas PharmaPhase 2
52
ASP2151 + PlaceboAstellas PharmaPhase 1
33
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
52
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
33
GSK1349572 + EfavirenzShionogiPhase 1
33
Zoster Vaccine, Live + Comparator: PlaceboMerckPhase 2
52
Comparator: V212 + Comparator: PlaceboMerckPhase 1
33
Zoster Vaccine, LiveMerckPhase 3
77
V212 + PlaceboMerckPhase 3
77
zoster vaccine live (ZOSTAVAX™) + Comparator: PlaceboMerckPhase 3
77
ZOSTAVAXMerckPhase 3
77
Zoster Vaccine, Live (AMP) + Zoster Vaccine, LiveMerckPhase 3
77
V212 + PlaceboMerckPhase 2
52
V212 + Matching placeboMerckPhase 3
77
V212 Lot 1 + V212 Lot 2 + V212 Lot 3MerckPhase 3
77
HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%MerckPhase 1
33
V212 + PlaceboMerckPhase 1
33
ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal + ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal + Full Dose Intradermal Placebo + Intradermal PlaceboMerckPhase 1
33
ZOSTAVAX™ (concomitant) + Comparator: Influenza Vaccine + ZOSTAVAX™ (Nonconcomitant)MerckPhase 3
77
ZOSTAVAX™MerckPre-clinical
23

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85